Welcome to our dedicated page for Tempest Therapeutics news (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.
Tempest Therapeutics, Inc. develops clinical-stage cell therapy and small-molecule product candidates for cancer and related disease areas. News about TPST centers on its dual-targeting CAR-T platform, including TPST-2003, a CD19/BCMA CAR-T therapy under development for relapsed or refractory multiple myeloma, and clinical updates from programs such as REDEEM-1 and POEMS-1.
Company updates also cover CAR-T manufacturing and technology-transfer work, partner-supported development activities, business development and licensing priorities, and the amezalpat small-molecule program. Recurring corporate news includes financial results, pipeline portfolio changes following acquired CAR-T assets, leadership appointments, and governance or capital-structure matters tied to the company’s Nasdaq-listed common stock.
Tempest (Nasdaq: TPST) delivered the TPST-2003 lentiviral vector to Cincinnati Children’s AGCTC, enabling manufacturing activities needed for pivotal development of the dual-targeting CD19/BCMA CAR-T for relapsed/refractory multiple myeloma.
Tempest reported a 100% overall response rate (25/25) across evaluable patients and 100% complete responses in six REDEEM-1 efficacy-evaluable patients; median PFS was 23.1 months in the investigator-initiated trial. Tech transfer is on track to support initiation of a potentially registrational study in Q4 2026.
Tempest (Nasdaq: TPST) appointed Andrew Fang, Ph.D., as Head of Business Development on April 14, 2026, to lead global partnerships, cross-border licensing and China outreach. The hire targets partnering for the Phase 3-ready small molecule amezalpat program and strategic collaborations across Tempest’s CAR-T portfolio.
The company noted prior regulatory alignment with FDA and EMA and clearance to pursue a pivotal trial of amezalpat in China, positioning the program for potential global development and regional licensing opportunities.
Tempest (Nasdaq: TPST) reported year-end 2025 results and a corporate update on March 30, 2026. Key developments include the strategic all-stock acquisition of dual-targeting CAR-T assets from Factor Bioscience, positive interim REDEEM-1 data for TPST-2003 (100% CR in six evaluable patients), regulatory designations for amezalpat, and multiple equity financings.
Financially, cash fell to $7.7M at year-end 2025 from $30.3M, net loss was $26.3M, R&D spend was $12.6M, and Tempest noted partner-funded development strategies moving forward.
Tempest Therapeutics (Nasdaq: TPST) announced a private placement expected to close on or about March 23, 2026 to raise up to $6 million in aggregate proceeds: approximately $2 million upfront and up to $4 million if warrants are fully exercised.
The offering covers 925,927 shares (or pre-funded warrants) and accompanying series A and short-term series B warrants priced at $2.16 per share; warrants require stockholder approval and have defined expiry periods. Proceeds are for working capital and general corporate purposes.
Tempest (Nasdaq: TPST) selected Cincinnati Children’s Applied Gene and Cell Therapy Center (AGCTC) to conduct technology transfer, development and IND‑enabling manufacturing for TPST-2003, a dual‑targeting CD19/BCMA CAR‑T for relapsed/refractory multiple myeloma.
As of a January 31, 2026 cutoff, 36 patients received TPST-2003; all six efficacy‑evaluable REDEEM-1 patients achieved complete response and overall response rate was 100% (25/25) among evaluable patients. Most activities are planned complete by Q3 2026 to support a potential IND filing in Q4 2026.
Tempest (NASDAQ: TPST) reported interim REDEEM-1 results for TPST-2003, a CD19/BCMA dual-targeting CAR-T. Across two studies 36 patients treated; among 25 evaluable with measurable disease ORR was 100% (25/25), and all six REDEEM-1 efficacy-evaluable patients achieved CR. Safety showed no Grade >=3 CRS or ICANS. Tempest plans a U.S. IND submission and, subject to clearance, to initiate a U.S. registrational study in 2026.
Tempest Therapeutics (Nasdaq: TPST) outlined a capital-efficient plan to advance newly acquired dual-targeting CAR-T assets, prioritizing partner-funded development to preserve internal capital. Key priorities include advancing TPST-2003 with near-term Phase 1 data from China, a registrational Phase 2b planned by end-2026, and interim data expected in 2027.
The pipeline expansion includes TPST-4003, an in vivo CD19/BCMA CAR-T program aimed at preclinical development and partner-funded investigator trials, plus continued development of amezalpat (Phase 3-ready HCC) and a NCI-funded Phase 2 for TPST-1495 with enrollment expected in Q1 2026.
Tempest (Nasdaq: TPST) closed an all-stock acquisition of dual-targeting CAR-T programs and secured strategic partner funding from Factor Bioscience, adding clinical-stage assets including TPST-2003. The deal extends operational runway to mid-2027, supports multiple near-term milestones, and installs Matt Angel, Ph.D., as President and CEO.
Key program highlights: TPST-2003 has completed a Phase 1 rrMM study with China BLA planned for 2027; TPST-2003 is enrolling POEMS patients with data and a China BLA planned by 2028; TPST-1120 remains Phase 3 ready in first-line HCC.
Tempest Therapeutics (Nasdaq: TPST) announced a record date of January 30, 2026 for a dividend distribution of warrants to purchase common stock (one warrant per share). The distribution is expected on February 3, 2026, subject to closing conditions under an Asset Purchase Agreement and stockholder approval of Proposal 5.
The warrants expire five years after distribution at 5:00 p.m. NYC and have an initial exercise price of $18.48 per share; exercisability requires an effective registration statement covering the underlying shares.
Tempest Therapeutics (Nasdaq: TPST) announced a registered direct offering of 1,172,414 shares at $3.625 per share for aggregate gross proceeds of approximately $4.25 million, and a concurrent private placement of short-term unregistered warrants to purchase up to 1,172,414 shares at an exercise price of $3.50.
The warrants are immediately exercisable, expire 18 months after the registration statement becomes effective, and could provide up to an additional $4.1 million if fully exercised. Closing is expected on or about November 25, 2025. Net proceeds are intended for working capital and general corporate purposes; H.C. Wainwright is placement agent.